reiter op
sector gener interest stock select import
sens increas investor interest larg cap pharma
space recent week driven reason valuat attract
risk/reward potenti signific upsid see posit
innov and/or eas least clariti drug price concern
last point becam acut week multipl announc
washington suggest could see chang drug
price us sooner later previous publish unifi
approach trump administr could provid real platform
chang wait detail administr may actual
limit manufactur abil rebat surpris us allow
drug re-import select situat continu prefer
stock driven innov new product stori avoid
stock compani heavili expos pricing/biosimilar risk
remain cautiou despit sell-off essenti
compani util rebat extent gain preferenti formulari
statu product uniqu howev given humira size
extent rebat support product
leverag compani humira sale earn
downgrad under-perform highlight concern around
humira longev face biosimilar competit also potenti
pressur us humira sale ahead includ decreas
begin impact profit step could taken overcom
rebat trap investor clearli focus
concern addit would highlight structur drug price
chang would also like neg impact uptak import
pipelin product upadacitinib risankizumab
hope leverag current payer relationship gain traction product
later market undifferenti vs key competitor
extract price
room upsid despit ytd move rais
keytruda estim ahead earn next week assum
top-line out-performance even notic greater
visibl anticip navig januvia patent cliff
ad addit growth driver would help believ keytruda
uptak continu drive addit upsid decis
increas averag net price portfolio inflat
annual chang view believ
get much level net price recent year anyway
net price across us portfolio actual declin
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
sensit analysi provid perspect
chang humira sale could impact dcf
given uncertainti around administr may chang us drug price
system chang might implement difficult know
chang may impact specif drug frame refer present
sensit analysi show chang us growth rate humira
prior expect us biosimilar entri would impact dcf valuat
base case dcf note current consensu estim
humira higher base case estim figur incorpor
consensu estim model would increas dcf
howev sensit analysi suggest reduct
compound-annual-growth-rate humira could lower dcf compani much per
share figur assum rapidli declin humira franchis would lead
increment sg reduct incorpor reduct
sensit analysi although could like reduc expens even
figur credit suiss estim humira current consensu
figur sensit analysi provid perspect chang humira sale expens
product sold ex-amort
tax earn
average share outstand
dilut ep oper
revenu
amort intang
equiti incom affili
total incom expens
provis incom tax
compani mention price
